SCHEMBL961175

SCHEMBL961175

O=[N+]([O-])c1cccc(CO)c1F

nearest known ligand 0.52

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.52
TSHR P16473 2/20 0.52
TDP1 Q9NUW8 3/20 0.50
GPR35 Q9HC97 2/20 0.48
CA12 O43570 1/20 0.47
HPGD P15428 1/20 0.43
ALDH3A1 P30838 1/20 0.41
PTPN1 P18031 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
ERN1 O75460 1/20 0.40
CA1 P00915 1/20 0.39
CA2 P00918 1/20 0.39
MMP1 P03956 1/20 0.39
MMP2 P08253 1/20 0.39
MMP9 P14780 1/20 0.39
MMP8 P22894 1/20 0.39
MMP13 P45452 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17141369 0.86 ALDH1A1 (0.49) ALDH1A1TSHRTDP1GPR35CA12
SCHEMBL12648507 0.83 TDP1 (0.50) ALDH1A1TSHRTDP1GPR35HPGD
SCHEMBL29842916 0.81 ALDH1A1 (0.47) ALDH1A1TSHRTDP1GPR35HPGD
SCHEMBL17141360 0.81 ALDH1A1 (0.67) ALDH1A1TSHRTDP1GPR35HPGD
SCHEMBL250079 0.81 ALDH1A1 (0.47) ALDH1A1TSHRTDP1GPR35HPGD
SCHEMBL68381 0.80 ALDH1A1 (0.70) ALDH1A1TSHRTDP1GPR35CA12
SCHEMBL29699944 0.80 ALDH1A1 (0.70) ALDH1A1TSHRTDP1GPR35CA12
SCHEMBL28901826 0.80 ALDH1A1 (0.46) ALDH1A1TSHRTDP1GPR35HPGD
SCHEMBL28156049 0.80 TDP1 (0.39) ALDH1A1TSHRTDP1GPR35CA12
SCHEMBL18589155 0.80 ALDH1A1 (0.43) ALDH1A1TSHRTDP1GPR35CA12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 65 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3547414-B1 LITHIUM ELECTRODE AND LITHIUM SECONDARY BATTERY COMPRISING SAME LG ENERGY SOLUTION LTD (KR) 2023-09-13 EP claimed
EP-3664213-B1 ELECTROLYTE FOR LITHIUM METAL BATTERY AND LITHIUM METAL BATTERY COMPRISING SAME LG ENERGY SOLUTION LTD (KR) 2023-09-13 EP claimed
US-11495824-B2 Electrolyte for lithium metal battery and lithium metal battery comprising same LG ENERGY SOLUTION, LTD. (KR) 2022-11-08 US claimed
CN-110192294-B Lithium electrode and lithium secondary battery comprising same 株式会社LG新能源 2022-09-20 CN claimed
CN-111033864-B Electrolyte for lithium metal battery and lithium metal battery comprising same 株式会社LG新能源 2022-08-12 CN claimed
US-20200203759-A1 ELECTROLYTE FOR LITHIUM METAL BATTERY AND LITHIUM METAL BATTERY COMPRISING SAME LG CHEM, LTD. (KR) 2020-06-25 US claimed
EP-3664213-A2 ELECTROLYTE FOR LITHIUM METAL BATTERY AND LITHIUM METAL BATTERY COMPRISING SAME LG Chem, Ltd. (KR) 2020-06-10 EP claimed
US-20190319272-A1 LITHIUM ELECTRODE AND LITHIUM SECONDARY BATTERY COMPRISING SAME LG CHEM, LTD. (KR) 2019-10-17 US claimed
EP-3547414-A2 LITHIUM ELECTRODE AND LITHIUM SECONDARY BATTERY COMPRISING SAME LG Chem, Ltd. (KR) 2019-10-02 EP claimed
US-12583821-B2 Salt of omecamtiv mecarbil and process for preparing salt CYTOKINETICS, INC. (US) 2026-03-24 US disclosed
EP-2970123-B2 CRYSTALLINE DIHYDROCHLORIDE HYDRATE SALT OF OMECAMTIV MECARBIL AND PROCESS FOR ITS PREPARATION AMGEN INC (US) 2025-12-10 EP disclosed
US-20250243163-A1 SALT OF OMECAMTIV MECARBIL AND PROCESS FOR PREPARING SALT AMGEN INC. 2025-07-31 US disclosed
US-12221417-B2 Salt of omecamtiv mecarbil and process for preparing salt CYTOKINETICS, INC. (US) 2025-02-11 US disclosed
US-20240317687-A1 SALT OF OMECAMTIV MECARBIL AND PROCESS FOR PREPARING SALT CYTOKINETICS, INC. 2024-09-26 US disclosed
US-20100004233-A1 NOVEL COUMARIN DERIVATIVE HAVING ANTITUMOR ACTIVITY CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2010-01-07 US disclosed
EP-2132184-A1 NOVEL PYRIMIDINE DERIVATIVES 698 AstraZeneca AB (SE) 2009-12-16 EP disclosed
EP-1982982-A1 NOVEL COUMARIN DERIVATIVE HAVING ANTITUMOR ACTIVITY CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2008-10-22 EP disclosed
US-20080242663-A1 NOVEL PYRIMIDINE DERIVATIVES 698 ASTRAZENECA AB (SE) 2008-10-02 US disclosed
US-20080242663-A1 NOVEL PYRIMIDINE DERIVATIVES 698 ASTRAZENECA AB (SE) 2008-10-02 US disclosed
WO-2008104754-A1 NOVEL PYRIMIDINE DERIVATIVES 698 ASTRAZENECA AB (SE) 2008-09-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250243163-A1 SALT OF OMECAMTIV MECARBIL AND PROCESS FOR PREPARING SALT SI, SLC5A6, SLC28A1 ALDH1A1 1835/4885TSHR 4307/4885TDP1 3853/4885
US-20080242663-A1 NOVEL PYRIMIDINE DERIVATIVES 698 EPHB4, EPHB1, NME2 ALDH1A1 1143/4885TSHR 2708/4885TDP1 588/4885
US-20240317687-A1 SALT OF OMECAMTIV MECARBIL AND PROCESS FOR PREPARING SALT SI, SLC5A6, SLC28A1 ALDH1A1 1835/4885TSHR 4307/4885TDP1 3853/4885
US-20100004233-A1 NOVEL COUMARIN DERIVATIVE HAVING ANTITUMOR ACTIVITY H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, SULT1A1, SULT1E1 ALDH1A1 452/4885TSHR 4227/4885TDP1 3965/4885
US-12583821-B2 Salt of omecamtiv mecarbil and process for preparing salt SLC28A2, SLC28A1, SLC5A11 ALDH1A1 1521/4885TSHR 2392/4885TDP1 3475/4885
US-12221417-B2 Salt of omecamtiv mecarbil and process for preparing salt SI, SLC5A6, SLC28A1 ALDH1A1 1835/4885TSHR 4307/4885TDP1 3853/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.